Page 1

Exhibit 99.1 AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update Provided comprehensive safety update on AVROBIO's lentiviral gene therapy platform and programs at ESGCT 2021 Received FDA feedback on CMC requirements for anticipated Fabry disease registration trial ; registration study initiation anticipated for mid - 2022 Cash runway extended into fourth quarter of 2023 Secured up to $ 65 million in availability of non - dilutive term loan financing CAMBRIDGE , Mass . , Nov. 4 , 2021 - AVROBIO , Inc. ( Nasdaq : AVRO ) , a leading clinical - stage gene therapy company with a mission to free people from a lifetime of genetic disease , today reported financial results for the quarter ended Sept. 30 , 2021 , and provided a business update . " We believe the data update provided at the 2021 European Society of Gene & Cell Therapy ( ESGCT ) Virtual Congress in October continues to strengthen the risk / benefit profile of our first - in - class lentiviral gene therapy platform , ” said Geoff MacKay , president and CEO of AVROBIO . " The safety data to date , combined with the efficacy and durability data previously announced , continue to support the potential of our one - time gene therapies to transform the lives of patients living with life - limiting lysosomal disorders . " Additionally , we recently received feedback from the U.S. Food and Drug Administration ( FDA ) on chemistry , manufacturing and controls ( CMC ) requirements for the Fabry disease registrational trial and are planning to successfully meet regulatory requirements prior to the planned initiation of the registration trial in mid - 2022 , ” adds MacKay . " Activities across the pipeline remain robust . With approximately two years of cash runway , and multiple data and regulatory updates as well as several trial initiations expected over the next 12 months , we head into 2022 with strong business momentum and in a solid financial position . " Program Updates and Milestones Received feedback from FDA in September 2021 on CMC requirements for Fabry disease registration trial : • Subsequent meeting to discuss trial design and confirm updated CMC plans expected to be held in first quarter of 2022 .